With regard to the therapeutic mechanism, previous studies have reported that administration of recombinant HGF protein (16) and vector encoding HGF gene (43) ameliorate TNBS-induced colitis and reduced inflammation, decreasing the levels of inflammatory cytokines such as TNF-α. This evidence concerns the gene TNF and colitis.